GlassScriptPhysician profile
Tadd L Selby
NPI 1699700377
$3,029.49
in general payments reported to CMS, 2019-2025
25 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $113 · 2021: $709 · 2022: $853 · 2023: $652 · 2024: $361 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.12 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,150.08 | 2019-2025 | Myrbetriq, Padcev, Xtandi |
| Procept Biorobotics Corporation | $368.22 | 2022-2023 | Aquabeam Robotic System |
| Abbvie INC. | $276.91 | 2020-2024 | Botox, Lupron Depot |
| Boston Scientific Corporation | $189.76 | 2019-2025 | Rezum Generator, Lithovue |
| Merck Sharp & Dohme LLC | $182.15 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Sumitomo Pharma America, INC. | $159.32 | 2023-2024 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $145.02 | 2021-2023 | |
| Pfizer INC. | $115.89 | 2019-2024 | |
| Urovant Sciences INC | $59.90 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $47.62 | 2021-2022 | |
| Allergan, INC. | $40.48 | 2021 | |
| Myovant Sciences INC. | $32.37 | 2021-2022 | |
| Urogen Pharma, INC. | $30.16 | 2023 | Jelmyto |
| Janssen Biotech, INC. | $29.27 | 2020-2023 | Erleada |
| Laborie Medical Technologies Corp. | $25.75 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $23.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.73 | 2023 | Oxlumo |
| Olympus America INC. | $22.12 | 2023 | Itind System |
| Tolmar, INC. | $21.21 | 2023 | |
| Endo Pharmaceuticals INC. | $20.08 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $15.45 | 2023 | Bard Urinary Drainage Bag |
| Blue Earth Diagnostics | $14.84 | 2021 | |
| Dentsply Ih INC. | $12.99 | 2019 | |
| Sagent Pharmaceuticals | $12.31 | 2022 | |
| Travere Therapeutics, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tadd Selby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.